You are here

Lipid Lowering agents use in periodontitis and diabetes study

Lipid Lowering agents use in periodontitis and diabetes study

This project will evaluate pathways linking type 2 diabetes and periodontitis by evaluating the association between regular statins use and reduced periodontitis, and local and systemic markers of inflammation in diabetic individuals. The project aims to evaluate the anti-inflammatory effects of (Lipid lowering agents use) LLA, through activation or up-regulation of peroxisome proliferator-activated receptors- gamma (PPAR-ɣ), on the occurrence of peridontitis among type 2 diabatic individuals. We hypothesize that diabetic individuals taking LLA, such as statins, will have high systemic levels of PPAR-ɣ, which, in turn, may lower local and systemic inflammatory responses to PD pathogens, thereby reducing the occurrence of PD compared with diabetic individuals LLA non-users.